Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in non-small cell lung cancer
- Trial result Spotlight
Non-small cell lung cancer
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC
CHORUS (NCT04905316) tested canakinumab, an anti–interleukin-1β monoclonal antibody intended to blunt protumor inflammation, given with concurrent chemoradiotherapy (cCRT) and continued alongside anti–PD-L1…
NCT04905316 - Trial result
Non-small cell lung cancer
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group
Aglatimagene besadenovec (CAN-2409) is a replication-defective adenoviral vector encoding HSV-thymidine kinase, designed to trigger immunogenic tumor cell death after exposure to valacyclovir while patients continue…
NCT04495153 - New trial
Non-small cell lung cancer
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC
This Phase 1, single-arm Georgetown University study tests whether five-fraction stereotactic body radiation therapy (SBRT) delivered on the Accuray CyberKnife system can safely control ultra-central, node-negative…
NCT07852247 Exploratory - New trial
Non-small cell lung cancer
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC
Chugai Pharmaceutical is running this first-in-human, open-label, multicenter Phase 1 study of AQUA07 alone and in combination with lorlatinib in advanced or metastatic ALK-positive NSCLC. Separate dose-escalation…
NCT07617337 First-in-human - Trial result
Non-small cell lung cancer
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC
In an exploratory post hoc analysis of the Phase III CROWN trial (NCT03052608), researchers evaluated an FDA-cleared AI tool for measuring brain metastases in 72 patients with untreated ALK+ advanced NSCLC and…
NCT03052608 - Trial result
Non-small cell lung cancer
Ociperlimab (TIGIT) + tislelizumab (PD-1) posts ~55% ORR in 1L NSCLC cohorts; 66% ORR in 1L ES-SCLC
Ociperlimab is an anti-TIGIT antibody combined here with tislelizumab, an anti–PD-1 antibody engineered to reduce Fcγ receptor binding; in AdvanTIG-105 (Phase I/Ib, open-label; NCT04047862), patients received…
NCT04047862 - New trial
Non-small cell lung cancer
Phase 2a TUB-040 NaPi2b-targeted topoisomerase 1 inhibitor ADC in nonsquamous NSCLC
Tubulis GmbH is running a randomized, open-label Phase 2a dose-optimization study of TUB-040, a NaPi2b (SLC34A2)–directed antibody-drug conjugate that delivers the topoisomerase 1 inhibitor payload exatecan into…
NCT07806773 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Savolitinib (MET TKI) + osimertinib boosts ORR to 49% when MET is truly “high” (IHC3+/≥90% and/or FISH10+)
Savolitinib is an oral, selective MET tyrosine kinase inhibitor being combined with osimertinib (3rd-gen EGFR TKI) to overcome MET-driven resistance after first-line osimertinib in EGFR-mutated advanced NSCLC in the…
NCT03778229 - Trial result
Non-small cell lung cancer
Osimertinib (EGFR TKI) Sustains 8-Year OS Benefit After Resected EGFR-Mutant NSCLC
Osimertinib is a 3rd-generation, CNS-penetrant EGFR tyrosine kinase inhibitor given for 3 years after surgery for EGFR exon 19 deletion or L858R-mutant NSCLC. In this long-term update of the Phase 3 ADAURA trial…
- Trial result Spotlight
Non-small cell lung cancer
Daraxonrasib (RMC-6236) RAS(ON) tri-complex inhibitor delivers 37% ORR in previously treated RAS-mutant NSCLC
Daraxonrasib (RMC-6236) is an oral, multiselective RAS(ON) tri-complex inhibitor that binds active, GTP-bound mutant and wild-type RAS isoforms; it was evaluated in the Phase 1–2 RMC-6236-001 study (NCT05379985) in…
NCT05379985 - Trial result
Non-small cell lung cancer
Durvalumab (PD-L1) + neoadjuvant chemo lifts pCR across lobectomy/sleeve/pneumonectomy in resectable NSCLC
Perioperative durvalumab, an anti–PD-L1 monoclonal antibody, was evaluated in AEGEAN, a double-blind Phase 3 trial (NCT03800134) in treatment-naïve, resectable stage II–IIIB (N2) NSCLC excluding EGFR/ALK-altered…
NCT03800134 - Trial result
Non-small cell lung cancer
Atezolizumab (PD-L1) + SBRT Fails to Improve OS—and Adds Toxicity—in High-Risk Early-Stage NSCLC (SWOG/NRG S1914)
Atezolizumab is an anti–PD-L1 monoclonal antibody added as induction, concurrent, and consolidation therapy around curative-intent stereotactic body radiation therapy (SBRT) in medically inoperable (or…
NCT04214262 - New trial
Non-small cell lung cancer
Phase 2/3 AMT-116 CD44v9-targeted topoisomerase I ADC vs docetaxel±ramucirumab in NSCLC.
This open-label, global, multicenter, randomized Phase 2/3 study from Multitude Therapeutics tests AMT-116, a CD44v9-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to…
NCT07718737 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Sutetinib (irreversible EGFR-TKI) drives 70.8% ORR and 13.7-mo PFS in 1L uncommon EGFR-mutant NSCLC
Sutetinib is an oral irreversible EGFR tyrosine kinase inhibitor (TKI) evaluated in a multicenter, open-label, single-arm Phase IIb trial in locally advanced/metastatic NSCLC with uncommon EGFR mutations (G719X,…
NCT05168566 - Trial result
Non-small cell lung cancer
Crizotinib (ALK TKI) Fails to Improve DFS as Adjuvant Therapy in Resected ALK+ NSCLC (E4512)
Crizotinib is a first-generation oral ALK tyrosine kinase inhibitor (TKI) evaluated as adjuvant therapy in the ECOG-ACRIN E4512 Phase 3 trial (NCT02201992) versus observation in resected early-stage ALK+ NSCLC (tumor…
NCT02201992 - Trial result
Non-small cell lung cancer
Ociperlimab (TIGIT) + tislelizumab (PD-1) with cCRT shows numerically longer PFS vs durvalumab in unresectable stage III NSCLC (AdvanTIG-301)
Ociperlimab is an anti-TIGIT antibody and tislelizumab is an anti–PD-1 antibody; AdvanTIG-301 (Phase III, open-label, randomized, multi-arm; NCT04866017) tested concurrent I/O with concurrent chemoradiotherapy (cCRT)…
NCT04866017 - New trial Spotlight
Non-small cell lung cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D-selective RAS(ON) inhibitor + pembrolizumab chemo in NSCLC
Revolution Medicines is running RASolve 308, a randomized, double-blind, placebo-controlled Phase 3 trial testing whether adding zoldonrasib (RMC-9805)—a KRAS G12D-selective, active-state “RAS(ON)” small-molecule…
NCT07777822 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 3 divarasib KRAS G12C inhibitor vs PD-1 immunotherapy/observation after resection.
Hoffmann‑La Roche’s KRASCENDO 3 (Phase 3, randomized, open-label) tests whether divarasib—an oral, covalent KRAS G12C small‑molecule inhibitor—improves outcomes versus investigator’s choice of pembrolizumab (Merck)…
NCT07541170 Registrational - New trial
Non-small cell lung cancer
Phase 1b NXP900 SRC family kinase inhibitor plus lorlatinib ALK/ROS1 inhibitor in ALK+ NSCLC.
This multi-center, open-label Phase 1b trial from Nuvectis Pharma tests escalating oral doses of NXP900 (a small-molecule SRC family kinase inhibitor) combined with lorlatinib (a small-molecule ALK and ROS1 tyrosine…
NCT07784959 Exploratory - New trial
Non-small cell lung cancer
Phase 2 SBRT “hot spot” dose-painting radiotherapy to intensify tumor hotspots in early NSCLC.
Roswell Park Cancer Institute is running PRESTO, a randomized Phase 2 trial testing whether intentionally creating higher-dose “hot spots” inside the tumor during stereotactic ablative radiotherapy (SABR/SBRT)—a…
NCT07718672 Exploratory - Trial result
Non-small cell lung cancer
Nivolumab/ipilimumab-based regimens lift 5-year survival in PD-L1–negative Japanese mNSCLC
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor), given first-line with or without 2 cycles of chemotherapy (CheckMate 227/9LA pooled), was analyzed in Japanese patients with metastatic NSCLC, PD-L1 <1%,…
- Trial result
Non-small cell lung cancer
Nivolumab (PD-1 blockade) + chemo: ctDNA clearance flags higher pCR and longer EFS in resectable NSCLC
Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor, was evaluated as perioperative therapy in the Phase 3, double-blind CheckMate 77T trial (NCT04025879): neoadjuvant nivolumab + platinum-doublet chemotherapy (4…
NCT04025879 - Trial result
Non-small cell lung cancer
Tiragolumab (anti‑TIGIT) + Atezolizumab Fails to Beat Durvalumab for PFS in Stage III NSCLC Consolidation
SKYSCRAPER-03 (Phase III, open-label; NCT04513925) tested tiragolumab, a TIGIT-checkpoint monoclonal antibody, plus atezolizumab (PD‑L1 inhibitor) as post–platinum concurrent chemoradiation consolidation versus…
NCT04513925 - Trial result
Non-small cell lung cancer
Taletrectinib (next-gen ROS1 TKI) linked to better PFS/OS than crizotinib/entrectinib in ROS1+ NSCLC (MAIC)
Taletrectinib is a next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) evaluated here via an unanchored matching-adjusted indirect comparison (MAIC) using pooled, single-arm TRUST-I (NCT04395677) and…
NCT04395677 - Trial result
Non-small cell lung cancer
Ociperlimab (anti‑TIGIT) + Tislelizumab (anti‑PD‑1) fails to beat pembrolizumab OS in PD‑L1≥50% 1L NSCLC
Ociperlimab is an anti‑TIGIT antibody combined with the anti‑PD‑1 tislelizumab to deepen checkpoint blockade; AdvanTIG‑302 (Phase 3; NCT04746924) randomized untreated stage III/IV (locally advanced unresectable or…
NCT04746924 - Trial result
Non-small cell lung cancer
PEF (irreversible electroporation) ablation + perioperative chemo‑IO delivers 75% pCR in resectable NSCLC (case series)
The VIGOR study (NCT05583188) evaluated adding neoadjuvant pulsed electric field (PEF) ablation (a non-thermal electroporation-based local tumor ablation) before standard-of-care neoadjuvant immune checkpoint…
NCT05583188 - Trial result
Non-small cell lung cancer
TRIDENT ML signature flags KRAS/STK11-mutant, EGFR/FGFR3/CDKN2A–WT non-squamous NSCLC for bigger tremelimumab add-on OS benefit
TRIDENT is a post hoc machine-learning analysis of the Phase 3 POSEIDON trial (NCT03164616; data cut-off March 12, 2021) evaluating whether adding tremelimumab (anti–CTLA-4) to durvalumab (anti–PD-L1) plus…
NCT03164616 - Trial result Spotlight
Non-small cell lung cancer
Ivonescimab (PD-1×VEGF bispecific) + pemetrexed/carboplatin extends OS after EGFR-TKI in NSCLC
Ivonescimab is a bispecific antibody that simultaneously targets PD-1 (checkpoint inhibition) and VEGF (anti-angiogenesis), aiming to pair immunotherapy with VEGF-pathway blockade in EGFR-variant nonsquamous NSCLC.…
NCT05184712 - Trial result
Non-small cell lung cancer
Alectinib (ALK TKI) shows bigger PFS edge in low tumor burden ALK+ NSCLC
A pooled individual patient-level analysis of the randomized Phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials compared first-line alectinib (a next-generation ALK tyrosine kinase inhibitor with CNS…
NCT02075840 - Trial result
Non-small cell lung cancer
Camrelizumab (PD-1) + chemo delivers 33% pCR in resectable stage III NSCLC, with ctDNA flagging relapse early
Camrelizumab is an anti–PD-1 monoclonal antibody given here with platinum-based chemotherapy as 3-cycle neoadjuvant chemoimmunotherapy in a single-arm Phase II study of resectable stage IIIA–IIIB NSCLC (n=30; 27…
NCT06241807
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.